Data / Drug companies / Amlodipine and valsartan
Amlodipine and valsartan: 10 companies and 40 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Amlodipine and valsartan is listed in the FDA National Drug Code Directory by 10 companies, with 40 products in commercial distribution. 40 of the products (100.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; tablet, film coated, and the newest product started marketing on October 22, 2026.
The request: Get every company that lists amlodipine and valsartan in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 10
- Products
- 40
- Generic (ANDA) products
- 40 (100.0%)
- Application numbers
- 8
- Routes
- Oral
- openFDA record search
- api.fda.gov
Companies that list amlodipine and valsartan
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Alembic Pharmaceuticals Inc. | 4 | tablet, film coated | Generic drugs (ANDA) | December 1, 2016 |
| Alembic Pharmaceuticals Limited | 4 | tablet, film coated | Generic drugs (ANDA) | December 1, 2016 |
| Aurobindo Pharma Limited | 4 | tablet, film coated | Generic drugs (ANDA) | April 22, 2016 |
| Cadila Pharmaceuticals Limited | 4 | tablet, film coated | Generic drugs (ANDA) | October 22, 2026 |
| Golden State Medical Supply, Inc. | 4 | tablet | Generic drugs (ANDA) | March 28, 2013 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 4 | tablet | Generic drugs (ANDA) | March 15, 2023 |
| Lupin Pharmaceuticals, Inc. | 4 | tablet | Generic drugs (ANDA) | March 31, 2015 |
| Lupin Pharmaceuticals,Inc. | 4 | tablet | Generic drugs (ANDA) | March 30, 2015 |
| Macleods Pharmaceuticals Limited | 4 | tablet | Generic drugs (ANDA) | October 16, 2024 |
| Mylan Pharmaceuticals Inc. | 4 | tablet, film coated | Generic drugs (ANDA) | March 30, 2015 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 20 | 50% |
| Tablet, film coated | 20 | 50% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 40 | 100% |
Pharmacologic classes
| Class | Products |
|---|---|
| Angiotensin 2 Receptor Blocker | 40 |
| Calcium Channel Blocker | 40 |
| Dihydropyridine Calcium Channel Blocker | 40 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.